You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study
|
|---|---|
| Published in |
BMC Infectious Diseases, February 2016
|
| DOI | 10.1186/s12879-016-1383-8 |
| Pubmed ID | |
| Authors |
Yan Zhang, Hainv Gao, Weifeng Liang, Lingling Tang, Yida Yang, Xiaoxin Wu, Liang Yu, Ping Chen, Shufa Zheng, Huilin Ou, Lanjuan Li |
| Abstract |
Since the novel H7N9 avian influenza outbreak occurred in China in 2013, neuraminidase inhibitors (NAIs) such as oseltamivir and peramivir have been used as first-line drugs to treat the influenza virus infection. This study aimed to compare the efficacy of oseltamivir-peramivir combination therapy versus oseltamivir monotherapy. A retrospective study of 82 H7N9 confirmed patients was conducted by reviewing medical charts at the First Affiliated Hospital of ZheJiang University in China from April 1, 2013 to Feb 28, 2014. The patients' clinical information was collected systematically, and we compared the virology and clinical data between oseltamivir monotherapy group (43 patients) and oseltamivir-peramivir combination group (39 patients). The median duration from NAIs administration to H7N9 virus-negative in oseltamivir monotherapy group and oseltamivir-peramivir combination group was 6.50 and 7.00 days (p >0.05), respectively. The median decline of Day 2 to Day 0 (initiation of NAIs therapy) viral load was 0.00 and 0.69 log10 copies/μl (p >0.05) respectively in the monotherapy vs. combination therapy groups. The incidence of new Acute Respiratory Distress Syndrome during NAI administration was 63.89 and 77.78 % (p >0.05); while the mortality rates were 25.58 and 43.59 % (p >0.05) in the oseltamivir group vs. oseltamivir-peramivir group. Our results suggest that in adults with H7N9 virus infection, the use of oseltamivir-peramivir combination therapy was not superior to oseltamivir monotherapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 16% |
| Student > Master | 5 | 16% |
| Professor | 2 | 6% |
| Student > Bachelor | 2 | 6% |
| Researcher | 2 | 6% |
| Other | 7 | 22% |
| Unknown | 9 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 34% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Agricultural and Biological Sciences | 2 | 6% |
| Social Sciences | 2 | 6% |
| Business, Management and Accounting | 1 | 3% |
| Other | 5 | 16% |
| Unknown | 9 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 February 2016.
All research outputs
#20,306,690
of 22,846,662 outputs
Outputs from BMC Infectious Diseases
#6,473
of 7,684 outputs
Outputs of similar age
#337,010
of 400,520 outputs
Outputs of similar age from BMC Infectious Diseases
#85
of 97 outputs
Altmetric has tracked 22,846,662 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,684 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 400,520 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 97 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.